Plandai Biotechnology Discusses Potential for Using Phytofare in Treating Type II Diabetes Other OTC:PLPL

Studies Point to Impact of Highly Bioavailable Catechins on Blood Sugar Regulation

LONDON, UNITED KINGDOM, June 12, 2018 (GLOBE NEWSWIRE) — Plandai Biotechnology, Inc. (OTCQB: PLPL) (“Plandai” or “the Company”), producer of the highly bioavailable Phytofare® catechin complex, today discussed the potential benefits of using highly-bioavailable green tea catechins, like those found in the Company’s proprietary Phytofare® extract, in treating people suffering from Type II diabetes.   Worldwide as of 2013, 382 million people, or 8.3% of the adult population, have diabetes, with Type II Diabetes making up about 90% of the cases.  In 2014, the International Diabetes Federation estimated that diabetes resulted in 4.9 million annual deaths.

Data from in vitro and in vivo studies suggest that green tea catechins, in particularly EGCG, may exert anti-obesity effects via several mechanisms including inhibition of adipocyte differentiation and proliferation, reduction of fat absorption, and reductions in fat mass, triglycerides, free fatty acids and total cholesterol.  The majority of human intervention studies investigating glucose homeostasis further demonstrate improved glucose levels in response to green tea catechins.  Human studies have shown anti-obesity, anti-diabetic and cardio-protective properties of green tea catechins (1).  

Leave a Reply

Your email address will not be published. Required fields are marked *